Complete financial analysis of Twist Bioscience Corporation (TWST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Twist Bioscience Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Blue Star Gold Corp. (BAUFF) Income Statement Analysis – Financial Results
- Jinneng Science&Techology Co.,Ltd (603113.SS) Income Statement Analysis – Financial Results
- Best Food Holding Company Limited (1488.HK) Income Statement Analysis – Financial Results
- Priveterra Acquisition Corp. (PMGMW) Income Statement Analysis – Financial Results
- Hind Aluminium Industries Limited (HINDALUMI.BO) Income Statement Analysis – Financial Results
Twist Bioscience Corporation (TWST)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.twistbioscience.com
About Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 312.97M | 245.11M | 203.57M | 132.33M | 90.10M | 54.39M | 25.43M | 10.77M | 2.27M |
| Cost of Revenue | 179.63M | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M | 32.19M | 24.02M | 9.42M |
| Gross Profit | 133.35M | 89.73M | 84.24M | 51.71M | 28.69M | 6.96M | -6.76M | -13.25M | -7.15M |
| Gross Profit Ratio | 42.61% | 36.61% | 41.38% | 39.08% | 31.85% | 12.80% | -26.59% | -123.09% | -315.20% |
| Research & Development | 90.85M | 106.89M | 120.31M | 69.07M | 43.01M | 35.68M | 20.35M | 19.17M | 18.23M |
| General & Administrative | 0.00 | 186.84M | 210.55M | 133.40M | 102.07M | 78.83M | 42.55M | 25.96M | 18.07M |
| Selling & Marketing | 0.00 | 2.90M | 2.40M | 2.50M | 1.20M | 1.30M | 900.00K | 100.00K | 200.00K |
| SG&A | 218.40M | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M | 43.45M | 26.06M | 18.27M |
| Other Expenses | 44.93M | 10.26M | -1.09M | -1.37M | -182.00K | -265.00K | -121.00K | -55.00K | 73.00K |
| Operating Expenses | 354.18M | 306.89M | 333.26M | 204.97M | 146.27M | 115.81M | 63.80M | 45.23M | 36.50M |
| Cost & Expenses | 533.81M | 462.27M | 452.59M | 285.59M | 207.68M | 163.24M | 95.99M | 69.25M | 45.93M |
| Interest Income | 15.34M | 14.37M | 3.06M | 435.00K | 1.50M | 3.03M | 999.00K | 412.00K | 241.00K |
| Interest Expense | 29.00K | 5.00K | 80.00K | 367.00K | 787.00K | 1.29M | 1.31M | 905.00K | 746.00K |
| Depreciation & Amortization | 31.43M | 29.31M | 36.64M | 11.99M | 6.68M | 6.31M | 5.73M | 5.02M | 4.23M |
| EBITDA | -176.71M | -174.15M | -191.55M | -143.91M | -132.09M | -99.77M | -63.95M | -53.10M | -39.11M |
| EBITDA Ratio | -56.46% | -71.05% | -121.36% | -116.52% | -129.04% | -195.06% | -251.52% | -493.21% | -1,723.80% |
| Operating Income | -220.83M | -217.16M | -249.02M | -153.26M | -117.58M | -108.85M | -70.56M | -58.48M | -43.66M |
| Operating Income Ratio | -70.56% | -88.60% | -122.33% | -115.81% | -130.50% | -200.15% | -277.50% | -543.16% | -1,924.02% |
| Total Other Income/Expenses | 12.67M | 13.69M | 6.50M | -1.30M | 530.00K | 1.47M | -435.00K | -548.00K | -432.00K |
| Income Before Tax | -208.17M | -203.47M | -228.27M | -154.03M | -139.55M | -107.38M | -70.99M | -59.03M | -44.09M |
| Income Before Tax Ratio | -66.51% | -83.01% | -112.14% | -116.39% | -154.88% | -197.44% | -279.21% | -548.25% | -1,943.06% |
| Income Tax Expense | 560.00K | 1.15M | -10.41M | -1.93M | 382.00K | 292.00K | 242.00K | 280.00K | 819.00K |
| Net Income | -208.73M | -204.62M | -217.86M | -152.10M | -139.93M | -107.67M | -71.24M | -59.31M | -44.09M |
| Net Income Ratio | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% | -550.85% | -1,943.06% |
| EPS | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| EPS Diluted | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| Weighted Avg Shares Out | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
| Weighted Avg Shares Out (Dil) | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
Twist Bioscience: Path To Profitability Beginning To Take Shape
Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges. The prospects of the biopharma segment are uncertain, highlighted by the sale of milestones and royalties to XOMA for a small amount. Twist's margins continue to...
Twist Bioscience: A Post-Earnings Assessment
Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for several years even as revenues rise. The company does have a solid...
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Founder Adam Laponis - CFO Patrick Finn - President and COO...
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.81 per share a year ago.
Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full...
Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation multiples now appear more reasonable, making it a compelling buy for new investors, with...
Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep™ Ultra-High Throughput Library Preparation Kit, designed with...
Twist Bioscience to Present at Baird Global Healthcare Conference 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present...
3 Healthcare AI Stocks Positioned for Potential Breakthroughs
Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were...
Source: https://incomestatements.info
Category: Stock Reports